Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels | CAI Stock NewsStockTitan·May 11 at 08:15 AMCAI-0.99%FBT-1.04%
Carasent Sets 14 April Date for Q1 2026 Results and WebcastTip Ranks·Apr 8 at 07:40 AMIBBQ-0.58%SBIO+0.52%
Carma issues new shares under employee incentive plan and confirms complianceTip Ranks·Mar 29 at 11:19 PMLABU-0.76%XLV-1.04%
Liberate Bio gains licences for myeloid-specific CAR design patentsPharmaceutical Technology·Mar 6 at 10:11 AMBBH-1.07%IBBQ-0.58%
Carma Director Owen Wilson Lifts Stake with On-Market Share PurchasesTip Ranks·Mar 4 at 01:59 AMCARM-22.22%CMA0.00%
Cancer Test Maker Caris Life Sciences Unveils Breakthrough In Early Cancer Detection, Profit Surprisebenzinga_article·Feb 27 at 12:00 PMIBB-0.88%VHT-0.97%
Carisma Therapeutics (OTCID: CARM) to voluntarily delist from Nasdaq, Board approved decision.Unusual Whales·Dec 5, 2025 at 04:18 PMCARM-22.22%
Carisma Announces Delisting from Nasdaq and SEC Deregistration | CARM Stock NewsStockTitan·Dec 5, 2025 at 08:16 AMCARM-22.22%
Carisma Therapeutics | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 45.25 MEarnings Watch·Nov 12, 2025 at 09:57 PMCARM-22.22%
